The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.00%)
Open: 20.50
High: 20.50
Low: 20.50
Prev. Close: 20.50
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

H1 Update and Updated Loan Facilities

20 Jul 2023 07:00

RNS Number : 5782G
Iofina PLC
20 July 2023
 

 

 

 

20 July 2023

 

Iofina plc

("Iofina", the "Company" or the "Group")

(AIM:IOF)

 

H1 Update and Updated Loan Facilities

 

Iofina plc (AIM:IOF), specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update on H1 2023 (the "Period") iodine production as well as an update on its loan facilities.

 

H1 2023 update

 

During the first half of 2023, Iofina Resources produced 241.5 metric tonnes ("MT") of crystalline iodine from its five IOsorb® plants in NW Oklahoma, within the projected range of 235-250 MT for the Period. This was an increase of 7.5 MT compared to H1 2022. 

 

With IO#9 switched on in June and working through its start-up phases and concentrating iodide, the Company anticipates a significant increase in H2 2023 crystalline iodine production totalling between 325-350 MT (H2 2022: 282 MT). This estimated production range is larger than normal as IO#9 continues to ramp up brine intake and is optimising parameters for its crystalline iodine production. The new plant will be contributing to the Group's total crystalline iodine production from this month.

 

The Company notes that the required configuration of IO#9 resulted in additional equipment and installation costs compared to other IOsorb® plants, which increased total expenditure including reused equipment to $5.5m. Future IOsorb® plant costs are anticipated to be less moving forward. Construction of IO#9 was funded entirely by cash generated from operations.

 

Iofina has continued to see strong demand for its crystalline iodine and derivative chemical products. Spot iodine prices have remained steady near $70/kg throughout the period, with iodine demand for use in X-ray contrast media and pharmaceuticals applications particularly strong. The Company expects these price levels to continue through the second half of the year.

 

Loan Facilities

 

The Company has recently renegotiated its undrawn loan facilities, securing a lower interest rate on agreements arranged last year, as follows:

 

a) The $2.7 million and $1.66 million term loans, which had not been utilized by Iofina, have been replaced by a $4 million term loan with a drawdown period open now through to July 1, 2024 to be used for IO#10 expenditures and other Capex projects as appropriate. A seven-year term begins from July 1, 2024 with interest payable during the drawdown period. The interest rate has been reduced from 2.4% to 2.11% plus SOFR (1 month Secured Overnight Financing Rate) subject to a minimum 1%.

 

b) The $6 million revolving line of credit has been extended by a year to 16 September 2025. The interest rate has been reduced from 2.4% to 2.11% plus SOFR subject to a minimum 1%. Iofina is currently not drawing on this line of credit. 

 

 

Commenting on the first half of the year, President and CEO of Iofina Dr. Tom Becker, stated: 

"I'm pleased to report on another successful period, with the completion of the IO#9 plant being the key milestone of the first half. With the ramp-up of IO#9 progressing, we are on course to deliver a considerable uplift in second-half production. Importantly, demand for our products remains high and we are benefiting from the iodine spot price maintaining its $70/kg level.

 

"Our discussions with prospective partners for IO#10 continue to move forward and we will provide a detailed update once an agreement has been reached. H1 has progressed well for the Group and the Board is looking forward to the second half of 2023."

 

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Henry Fitzgerald-O'Connor/Patrick Dolaghan/Andrew Potts

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

 

Financial Adviser:

Kingsley Wilson

Chrystal Capital Partners LLP

Tel: +44 (0)20 7850 4761

 

Media Contact:

Charles Goodwin/Shivantha Thambirajah/Jazmine Clemens

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

About Iofina:

Iofina plc (AIM:IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

 

LEI: 213800QDMFYVRJYYTQ84

 

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical will be celebrating its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGMNRLMGFZM
Date   Source Headline
26th Aug 20207:00 amRNSDebt Update
31st Jul 20208:00 amRNSLaunch of new website
22nd Jul 202011:06 amRNSSecond Price Monitoring Extn
22nd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSCorporate Update
30th Jun 20202:36 pmRNSDebt Update
30th Jun 202011:52 amRNSResult of AGM
26th Jun 20201:26 pmRNSChange of venue for AGM on 30 June 2020
26th Jun 20207:00 amRNSIO#8 and Debt Update
27th May 20207:00 amRNSFinal Results
19th May 20204:41 pmRNSSecond Price Monitoring Extn
19th May 20204:36 pmRNSPrice Monitoring Extension
15th May 20204:40 pmRNSSecond Price Monitoring Extn
15th May 20204:35 pmRNSPrice Monitoring Extension
14th May 20207:00 amRNSPPP Loan Received
4th May 20207:00 amRNSIO#8 Brine Supply Update
14th Apr 20207:00 amRNSQ1 Market Update
2nd Apr 20207:00 amRNSDirectorate Change
26th Mar 20201:53 pmRNSWithdrawal of requisition for General Meeting
19th Mar 202012:08 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
17th Mar 20204:41 pmRNSSecond Price Monitoring Extn
17th Mar 20204:35 pmRNSPrice Monitoring Extension
16th Mar 202012:07 pmRNSSecond Price Monitoring Extn
16th Mar 202012:02 pmRNSPrice Monitoring Extension
12th Mar 20204:41 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 20201:56 pmRNSClarification Regarding Media Reports
11th Mar 202012:08 pmRNSSecond Price Monitoring Extn
11th Mar 202012:02 pmRNSPrice Monitoring Extension
10th Mar 20207:30 amRNSBoard response to recent GM request
10th Mar 20207:00 amRNSRequisition of General Meeting
3rd Mar 20207:10 amRNSStatement re: press and social media reports
2nd Mar 202012:22 pmRNSHolding(s) in Company
25th Feb 202012:00 pmRNSMarket Update
10th Feb 20205:15 pmRNSHolding(s) in Company
10th Feb 20205:15 pmRNSHolding(s) in Company
16th Jan 20207:00 amRNSMarket Update - Strong H2 2019
2nd Jan 202011:11 amRNSHolding(s) in Company
20th Dec 20197:00 amRNSTrading Update
14th Nov 20193:51 pmRNSHolding(s) in Company
14th Nov 20193:50 pmRNSHolding(s) in Company
12th Nov 20191:43 pmRNSHolding(s) in Company
6th Nov 20197:00 amRNSIofinaEX Hemp Seed Investment
14th Oct 20197:00 amRNSQ3 2019 Update
26th Sep 201910:00 amRNSHolding(s) in Company
25th Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSInterim Results
18th Sep 20197:00 amRNSTerms for IO#8 Finalised - Construction Commences
29th Aug 20194:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.